For years, measuring a key indicator of gut health has required expensive laboratory equipment, specialist expertise and days of waiting for results. That may soon change.
Researchers in Singapore have developed a fluorescent nanosensor capable of detecting indole-3-propionic acid (IPA), a molecule produced by beneficial gut bacteria that is increasingly recognised as an important indicator of digestive and metabolic health.
The breakthrough could eventually pave the way for rapid, low-cost tests that help doctors diagnose intestinal diseases earlier, monitor treatment more effectively and even allow patients to track their gut health from home.
The research, led by scientists from the National Institute of Education at Nanyang Technological University (NTU), the Singapore-MIT Alliance for Research and Technology (SMART), the National University Hospital (NUH) and the Yong Loo Lin School of Medicine at the National University of Singapore, was recently published in the journal Advanced Healthcare Materials.
Why IPA matters
IPA is not a household name, but scientists have become increasingly interested in the molecule because of what it reveals about the trillions of bacteria living in the human digestive system.
Produced when gut microbes break down the amino acid tryptophan, IPA helps regulate inflammation and protect cells against oxidative stress. Low levels of the compound have been associated with inflammatory bowel disease (IBD), Type 2 diabetes and certain liver diseases.
Despite its growing importance, IPA has remained difficult to measure.
Current testing depends on mass spectrometry, a sophisticated laboratory technique that is accurate but costly, time-consuming and generally unavailable outside specialised research or hospital laboratories.
“Our approach provides the first optical nanosensor specifically designed to detect IPA rapidly in biological samples,” said Assistant Professor Mervin Ang of NTU, one of the study’s lead authors.
Instead of relying on complex laboratory analysis, the new sensor uses fluorescence. When IPA is present, the nanosensor produces an optical signal that can be measured within minutes.
Equally important, the researchers say, it can distinguish IPA from other closely related molecules commonly found in blood, improving accuracy even in complex biological samples.
From plants to patients
Interestingly, the technology did not begin in medicine.
The sensing platform was originally developed by SMART researchers to monitor plant health by measuring hormones and stress signals in crops.
Scientists later adapted the same molecular recognition technology to identify biomarkers in the human digestive system.
“This work builds on technology we originally developed for agriculture,” said Professor Michael Strano of the Massachusetts Institute of Technology and SMART. “We have now applied it to one of the long-standing challenges in gut health.”
The researchers believe the technology could eventually support more personalised healthcare by providing near real-time information about gut function.
To evaluate its medical potential, the team tested the nanosensor on 125 blood plasma samples collected from healthy volunteers and patients with gastrointestinal diseases.
The results showed clear differences in IPA levels between healthy individuals and patients with inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. Those experiencing active inflammation consistently had lower IPA levels, matching findings from previous clinical studies.
“For clinicians, having a rapid and relatively simple way to measure metabolites like IPA could complement existing diagnostic tools,” said Adjunct Associate Professor Jonathan Lee, senior consultant in gastroenterology and hepatology at the National University Hospital.
Toward home-based monitoring
The researchers envision applications well beyond hospitals.
Because the nanosensor operates in both visible fluorescence and near-infrared modes, future versions could be incorporated into portable diagnostic devices or wearable technologies capable of continuously monitoring gut health.
Such devices could help patients with chronic digestive diseases detect flare-ups earlier, monitor how well treatments are working or even assess how dietary changes and probiotics affect their gut microbiome.
Unlike many existing microbiome tests, which identify the types of bacteria living in the gut, the new sensor measures what those bacteria are actually producing. Researchers say this could provide a more direct picture of gut function and overall health.
For a field that has long depended on expensive laboratory analysis, that could represent a significant step toward making personalised gut health monitoring part of everyday healthcare. – Nanyang Technological University, Singapore
